Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Why BMY Stock dropped -2.06% Today — RQD Quant Desk Flash
Bristol-Myers Squibb Company (BMY) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-22, Bristol-Myers Squibb Company (NYSE: BMY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $58.34 (-2.06% 1D, market cap $119.24B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BMY ranks #183 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BMY compare to SNY and VRTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMY carries a Roarable D+ (54/100 RQD), trailing P/E of 17.8x, gross margin of 71.1%, and ROIC of 13.3%. By comparison, SNY (Sanofi ADS) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B) and VRTX (Vertex Pharmaceuticals Incorporated) posts a B grade (73/100 RQD, P/E 34.6x, ROIC 20.0%, cap $132.01B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BMY?
▼
Per BMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000014272), Bristol-Myers Squibb Company generated $48.19B in revenue (-0.2% YoY), $7.05B in net income, and $12.85B in free cash flow against $90.04B in total assets and $42.85B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where to Enter $BMY, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Altman Z-Score 2.24 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9
Macro rate sensitivity & RSI-14 (39.5) create a -15 pt regime headwind
⚔️ Adversarial Opposing Case: What Could Spark a BMY Turnaround Squeeze
While BMY currently carries a cautious 54/100 (D+) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Company leadership has skin in the game with net positive insider conviction.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($61.45) and Max Pain ($61.26) forces dealer call-delta covering toward $72.07.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why BMY Stock dropped -2.06% Today — RQD Quant Desk Flash
Bristol-Myers Squibb Company (BMY) dropped -2.06% to $58.34, trading at 51% of its 52-week range ($47.58 – $68.64). Stretched risk/reward at 18x P/E (13% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 51% of its 52-week range ($47.58 – $68.64) with RSI-14 at 39.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $58.34 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 71.1% gross margin and $12.8B annual free cash flow.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
Bristol Myers Squibb’s third quarter results reflected robust growth in its core portfolio, led by strong commercial execution and momentum across newer products. Management pointed to double-digit sales gains in key bra
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMY)
- ✓Walkthrough of BMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
BMY Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs
Test Your Own BMY Growth & WACC Assumptions
BMY passes the 8-variable Beneish M-Score audit (< -1.78), confirming GAAP earnings are backed by real operating cash flow.
BMY clears the 2.99 Altman Z-Score threshold with negligible 24-month credit distress risk.
BMY generates a positive 6.7% spread over WACC (6.6%), indicating competitive stability.
BMY reduced diluted share count YoY, increasing each shareholder’s ownership slice of free cash flow.
BMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMY. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMY)
1. Head-to-Head Health Care Peer Comparison (BMY vs. SNY, VRTX, GSK, REGN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Bristol-Myers Squibb Company (BMY) ranks #183 by composite RQD confidence (54/100, grade D+) and #20 by equity capitalization ($119.24B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with BMY at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BMY
ACTIVE
Bristol-Myers Squibb Company | D+ | 54/100 | 17.8x | 71.1% | 13.3% | -2.06% | $119.24B | Benchmark Subject |
| SNY Sanofi ADS | C | 62/100 | 32.8x | — | 9.9% | -2.25% | $112.33B | /sny-vs-bmy → |
| VRTX Vertex Pharmaceuticals Incorporated | B | 73/100 | 34.6x | 86.2% | 20.0% | -2.94% | $132.01B | /vrtx-vs-bmy → |
| GSK GSK plc American | D+ | 53/100 | 32.8x | — | 9.9% | -1.54% | $96.75B | /gsk-vs-bmy → |
| REGN Regeneron Pharmaceuticals Inc. | A- | 83/100 | 18.7x | — | 9.4% | -2.35% | $95.52B | /regn-vs-bmy → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000014272 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bristol-Myers Squibb Company (BMY) reported GAAP revenue of $48.19B (-0.2% vs. FY2024 revenue of $48.30B , and +7.1% cumulative change since FY2023) , GAAP net income of $7.05B, operating cash flow of $14.16B, and free cash flow of $12.85B (-7.9% YoY). On the balance sheet, BMY closed FY2025 with $90.04B in total assets against $42.85B in total debt (Altman Z-Score: 2.24, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $48.19B | $7.05B | $14.16B | $12.85B | $90.04B | $42.85B |
| FY2024 (FY) | 2024-12-31 | $48.30B | -$8.95B | $15.19B | $13.94B | $92.60B | $47.60B |
| FY2023 (FY) | 2023-12-31 | $45.01B | $8.03B | $13.86B | $11.83B | $68.97B | $16.14B |
3. BMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-22, Bristol-Myers Squibb Company (NYSE: BMY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $58.34 (-2.06% 1D, market cap $119.24B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BMY ranks #183 in composite RQD confidence.
How does BMY compare to SNY and VRTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMY carries a Roarable D+ (54/100 RQD), trailing P/E of 17.8x, gross margin of 71.1%, and ROIC of 13.3%. By comparison, SNY (Sanofi ADS) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B) and VRTX (Vertex Pharmaceuticals Incorporated) posts a B grade (73/100 RQD, P/E 34.6x, ROIC 20.0%, cap $132.01B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BMY?
Per BMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000014272), Bristol-Myers Squibb Company generated $48.19B in revenue (-0.2% YoY), $7.05B in net income, and $12.85B in free cash flow against $90.04B in total assets and $42.85B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BMY trading relative to its 50-day, 200-day, and 52-week technical levels?
BMY last traded at $58.34 (-2.06% on volume of 13,676,891 shares), positioning the stock -5.06% below its 50-day simple moving average ($61.45) and -3.46% below its 200-day simple moving average ($60.43). Across its 52-week range of $47.58 to $68.64, BMY sits at the 51.1% percentile with a 14-day RSI of 39.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($55.13 to $61.55).
BMY — Bristol-Myers Squibb Company: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Bristol-Myers Squibb Company (BMY) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $58.34 (-2.06% 1D, market capitalization $119.24B).
- Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 13.3%, gross margin of 71.1%, operating margin of 17.9%, and free cash flow yield of 10.24%.
- Whale 13F & Options Flow (9/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (5/20) + Forensic Balance Sheet (12/20): Incorporates a 0.98x equity beta, Altman Z-Score of 2.24, Piotroski F-Score of 7/9, and Debt/Equity of 2.32x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Bristol-Myers Squibb Company is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It carries a market capitalization of $125.4B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bristol-Myers Squibb Company (BMY) reported $48.19B in annual revenue (up from $48.30B in FY2024, -0.2% YoY) and $7.05B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($45.01B revenue, $8.03B net income) through FY2025, BMY scaled operating cash flow to $14.16B and free cash flow to $12.85B, backed by $90.04B in total assets against $42.85B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 54/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 10.24% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $47.58 – $68.64 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 17.8x trailing P/E and 16.3x EV/EBITDA against 17.9% operating margins and a 0.98x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from suppliers, customers, or peer companies.
- Key Question #1: Can BMY sustain or expand its 17.9% operating margin and 13.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $48.19B and free cash flow of $12.85B, how will capital allocation balance growth reinvestment against $42.85B in total debt?
- Key Question #3: How sensitive is BMY's 16.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?
BMY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bristol-Myers Squibb Company (BMY) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.
BMY Bull vs. Bear Conversation Board — What's Your Call at $58.34?
A 10.24% FCF yield and 13.3% ROIC show strong cash generation, with forward P/E of 16.6 below the trailing 17.8.
The street is overcomplicating Bristol-Myers Squibb Company (BMY). A 10.24% FCF yield and 13.3% ROIC show strong cash generation, with forward P/E of 16.6 below the trailing 17.8.. With an RQD score of 67/100 (C+) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $67.48.
@MeanReversion_88 Fair point on 17.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (71.1%) holds, EPS grows into the multiple faster than bears think.
Debt/Equity of 2.32 and EV/EBITDA of 16.3 leave the balance sheet leveraged and the enterprise not cheap despite the cash yield.
I respect the product at Bristol-Myers Squibb Company, but the stock at $62.48 is a different story. Debt/Equity of 2.32 and EV/EBITDA of 16.3 leave the balance sheet leveraged and the enterprise not cheap despite the cash yield.. FCF yield is 10.24% and RQD sits at 67/100 (C+) — why pay up here when you can wait for next quarter's numbers?
3 Stocks on Our Radar Today — Entry, Hard Stop & Why
BMY Stock & RQD Cockpit — Related SEC 10-K, Valuation Formula & Insider Research Hubs
Contextual Institutional Research Paths: Audit the step-by-step SQ 2-Stage DCF Intrinsic Value Calculator , verify balance-sheet solvency via the SQ Altman Z-Score 5-Ratio Test and SQ Piotroski 9-Point F-Score , or screen the broader equity universe using the Best Stocks to Buy Now Screener and Hot Stocks & Movers Today Screener .
Rotated Stock & Insider Dossiers: Cross-reference institutional dossiers on NVIDIA Corp. ($NVDA) ( NVDA WACC ), KLA Corp. ($KLAC) ( KLAC Piotroski F-Score ), and Constellation Energy ($CEG) , alongside verified insider trading disclosures for Sen. Bill Hagerty (U.S. Senate (R-TN)) and Sen. Sheldon Whitehouse plus macro regime telemetry on US High-Yield Credit Spread (OAS) (BAMLH0A0HYM2) .
- NVIDIA Corp. ($NVDA) [WACC] [Financials] [10-K RED]
- KLA Corp. ($KLAC) [Piotroski F-Score] [Dividends] [10-K DES]
- Constellation Energy ($CEG) [Peter Lynch Value] [Insiders] [10-K RED]
- Meta Platforms ($META) [PEG Ratio] [Financials] [10-K DES]
- Quanta Services ($PWR) [WACC] [Dividends] [10-K RED]
- Datadog Inc. ($DDOG) [Piotroski F-Score] [Insiders] [10-K DES]
- Vertex Pharmaceuticals ($VRTX) [Peter Lynch Value] [Financials] [10-K RED]
- Mastercard Inc. ($MA) [PEG Ratio] [Dividends] [10-K DES]
- Uber Technologies ($UBER) [WACC] [Insiders] [10-K RED]
- Home Depot ($HD) [Piotroski F-Score] [Financials] [10-K DES]
- Oklo Inc. ($OKLO) [Peter Lynch Value] [Dividends] [10-K RED]
- Reddit Inc. ($RDDT) [PEG Ratio] [Insiders] [10-K DES]
- Micron Technology ($MU) [WACC] [Financials] [10-K RED]
- Applied Materials ($AMAT) [Piotroski F-Score] [Dividends] [10-K DES]
- 📐 All 12 Institutional Valuation & Forensic Formulas (/term)
- 🔥 Best Stocks to Buy Now Screener (Top RQD Composite Score (A/A+) + Positive Momentum + Institutional / Insider Accumulation)
- ⚡ Hot Stocks & Movers Today Screener (Largest Daily % Price Swing + High Beta (> 1.25x) + Active Options & Momentum Signal)
- 🎯 Penny Stocks to Watch Screener (Low Share Price (≤ $8.00) + High Beta Volatility + Solvency Floor Filter)
- 💵 Stocks Under $5 Screener (Share Price ≤ $5.50 (or Lowest-Priced Decile) + High Beta + RQD Momentum Rank)
- 🔟 Stocks Under $10 Screener (Share Price ≤ $12.00 (or Lowest-Priced Tier) + Positive Revenue/Cash Trajectory + High RQD Score)
- 🏛️ Congress Stock Tracker Screener (Verified Congressional (House/Senate) Buy or C-Suite Form 4 Accumulation + Live RQD Grade)
- 🏰 Buffett-Munger Moat Screener (ROIC > 15%)
- 📈 Peter Lynch GARP Screener (Spot Price ≤ Peter Lynch Fair Value Line)
- 🛡️ Ben Graham Value Screener (Positive DCF Margin of Safety)
- 🔬 Piotroski F-Score 8–9 Screener (Piotroski F-Score ≥ 7/9)
- 👔 CEO & Congress Buys Screener (Verified Open-Market CEO/CFO Form 4 Buy or Congressional Accumulation + High RQD Cash Engine)
- 💰 High-ROIC Cash Cows Screener (FCF Yield ≥ 4.0%)
- 🚀 Quality Short Squeezes Screener (Elevated Short Interest / Beta + Piotroski F-Score ≥ 6/9 + Safe Altman Z-Score (> 2.2))
- 🚨 Forensic Red Flags Screener (Elevated Dilution (> +2.5% YoY) OR WACC > ROIC OR Extended Valuation Above DCF Band)
- ⚔️ SOFI vs. HOOD Revenue Velocity
- ⚔️ CRWD vs. PANW Cybersecurity Growth
- ⚔️ CAT vs. DE Industrial Capital Efficiency
- ⚔️ IREN vs. CORZ AI Grid Substation Margins
- ⚔️ VRT vs. ETN Liquid Cooling & Grid ROIC
- ⚔️ AAPL vs. MSFT Return on Capital (ROIC)
- 🏛️ Sen. Bill Hagerty (U.S. Senate (R-TN)) — $JPM Trades
- 🏛️ Sen. Sheldon Whitehouse (U.S. Senate (D-RI)) — $NEE Trades
- 🏛️ Sen. John Boozman (U.S. Senate (R-AR)) — $WMT Trades
- 🏛️ Rep. Rick Larsen (U.S. House (D-WA-02)) — $GE Trades
- 🏛️ Rep. Pete Sessions (U.S. House (R-TX-17)) — $GS Trades
- 🏛️ Rep. Kevin Hern (U.S. House (R-OK-01)) — $CVX Trades
- 🏛️ Sen. Mitch McConnell (Spouse) (U.S. Senate (R-KY)) — $CAT Trades
- 🏛️ Rep. Blake Moore (U.S. House (R-UT-01)) — $RKLB Trades
- 🐋 Bridgewater Associates — Global Macro Risk Parity 13F
- 🐋 Kathleen T. Hogan (Microsoft EVP) — Verified Form 4 Track Record
- 🐋 Citadel Advisors (Ken Griffin) — Multi-Strategy 13F Flow
- 🐋 Duquesne Family Office (Druckenmiller) — Macro & AI Infrastructure 13F
- 🐋 Pershing Square (Bill Ackman) — High-Conviction Compounders 13F
- 🐋 Viking Global Investors — TMT & Industrial Growth 13F
- 📰 Uber’s Post-Earnings Dip Is a Gift: Why Asset-Light Dispatch Networks Monetize Autonomous Fleets Faster Than Hardware Makers ($UBER)
- 📰 The Custom ASIC Threat Is Louder Than It Is Large: Blackwell Ultra Rack Math Says Otherwise ($NVDA)
- 📰 Broadcom Is Quietly Running Two Compounding Engines: Custom AI XPUs and a VMware Cash Machine ($AVGO)
- 📰 Wall Street Just Sold the Monopoly and Bought the Bottleneck ($GEV)
- 📰 The $310 Billion AI Capex Reality Check: Why Hyperscaler Free Cash Flow Is Compressing — And the 4 Grid & Cooling Monopolies Actually Pocketing the Cash ($VRT)
- 📰 The 15% Yield Mirage: Why We Are Swapping Mortgage REIT Book-Value Erosion (AGNC) for Triple-Net Cash Compounders (VICI & EPD) ($VICI)
- 📊 US High-Yield Credit Spread (OAS) (BAMLH0A0HYM2)
- 📊 10-Year US Treasury Benchmark Yield (DGS10)
- 📊 Effective Federal Funds Policy Rate (FEDFUNDS)
- 📊 Federal Reserve Total Assets (WALCL) (WALCL)
- 📊 Headline Consumer Price Index (CPI-U) (CPIAUCSL)
- 💡 Defense & Space DoD Obligations Backlog Thesis
- 💡 Starter Kit: AI Power, Liquid Cooling & Substation Grid
- 💡 AI Power Bottleneck & Hyperscaler CapEx Thesis
- 💡 Share-Count Creep, SBC Dilution & 2027 Refinancing Watch
- 💡 Weekly Evidence Audit: Confirmed vs. Overpriced Options
- 🦋 2nd-Order Supply-Chain & Grid Butterfly Map (/butterfly)
- 🔬 30-Second Portfolio Crash & Overlap X-Ray (/xray)
- 🎯 Real-Time Macro Event Probability Engine (/predictions)
- 🏆 $100K Risk-Free Paper Trading Simulation Arena (/arena)